Search Results

FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease.

The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for avalglucosidase alfa for long-term enzyme ...
Nov 20